- Home
- SLNO vs PTGX Comparison
SLNO vs PTGX Comparison
Compare SLNO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- PTGX
- Stock Information
- Founded
- SLNO 1999
- PTGX 2006
- Country
- SLNO United States
- PTGX United States
- Employees
- SLNO N/A
- PTGX N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- PTGX Health Care
- Exchange
- SLNO Nasdaq
- PTGX Nasdaq
- Market Cap
- SLNO 3.8B
- PTGX 4.0B
- IPO Year
- SLNO 2014
- PTGX 2016
- Fundamental
- Price
- SLNO $65.46
- PTGX $77.57
- Analyst Decision
- SLNO Strong Buy
- PTGX Strong Buy
- Analyst Count
- SLNO 9
- PTGX 8
- Target Price
- SLNO $116.78
- PTGX $74.13
- AVG Volume (30 Days)
- SLNO 1.7M
- PTGX 1.6M
- Earning Date
- SLNO 11-05-2025
- PTGX 11-06-2025
- Dividend Yield
- SLNO N/A
- PTGX N/A
- EPS Growth
- SLNO N/A
- PTGX N/A
- EPS
- SLNO N/A
- PTGX 0.80
- Revenue
- SLNO $32,656,999.00
- PTGX $209,180,000.00
- Revenue This Year
- SLNO N/A
- PTGX N/A
- Revenue Next Year
- SLNO $182.29
- PTGX $243.08
- P/E Ratio
- SLNO N/A
- PTGX $96.33
- Revenue Growth
- SLNO N/A
- PTGX N/A
- 52 Week Low
- SLNO $41.50
- PTGX $33.31
- 52 Week High
- SLNO $90.32
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- SLNO 51.66
- PTGX 63.15
- Support Level
- SLNO $63.02
- PTGX $74.62
- Resistance Level
- SLNO $72.88
- PTGX $93.25
- Average True Range (ATR)
- SLNO 4.25
- PTGX 4.76
- MACD
- SLNO 1.03
- PTGX 0.80
- Stochastic Oscillator
- SLNO 56.61
- PTGX 49.44
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.